These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2242095)

  • 1. Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: implications for drug discovery.
    Gillies PJ; Robinson CS; Rathgeb KA
    Atherosclerosis; 1990 Aug; 83(2-3):177-85. PubMed ID: 2242095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: role of a cholesterol substrate pool.
    Gillies PJ; Rathgeb KA; Perri MA; Robinson CS
    Exp Mol Pathol; 1986 Jun; 44(3):329-39. PubMed ID: 3720921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
    Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.
    Asami Y; Yamagishi I; Murakami S; Araki H; Tsuchida K; Higuchi S
    Life Sci; 1998; 62(12):1055-63. PubMed ID: 9519807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.
    Bocan TM; Mueller SB; Uhlendorf PD; Newton RS; Krause BR
    Arterioscler Thromb; 1991; 11(6):1830-43. PubMed ID: 1931885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-atherosclerotic properties of the acyl-coenzyme A:cholesterol acyltransferase inhibitor F 12511 in casein-fed New Zealand rabbits.
    Rival Y; Junquéro D; Bruniquel F; N'Guyen X; Fauré P; Pomiès JP; Degryse AD; Delhon A
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):181-91. PubMed ID: 11791003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.
    Perrey S; Legendre C; Matsuura A; Guffroy C; Binet J; Ohbayashi S; Tanaka T; Ortuno JC; Matsukura T; Laugel T; Padovani P; Bellamy F; Edgar AD
    Atherosclerosis; 2001 Apr; 155(2):359-70. PubMed ID: 11254906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyl-coenzymeA (CoA):cholesterol acyltransferase inhibition in rat and human aortic smooth muscle cells is nontoxic and retards foam cell formation.
    Rong JX; Kusunoki J; Oelkers P; Sturley SL; Fisher EA
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):122-7. PubMed ID: 15499046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
    Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
    Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal evaluation of fatty acid-binding protein (FABP) activity in association with the development of atherosclerosis in the rabbit.
    St John LC; Bell FP
    Comp Biochem Physiol Comp Physiol; 1992 Jun; 102(2):357-61. PubMed ID: 1354584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased microsomal membrane fluidity in the development of cholesterol-induced atherosclerosis in the rabbit.
    Robinson C; Gillies P
    Exp Mol Pathol; 1986 Dec; 45(3):294-302. PubMed ID: 3792513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential antiatherosclerotic agents. 6. Hypocholesterolemic trisubstituted urea analogues.
    DeVries VG; Bloom JD; Dutia MD; Katocs AS; Largis EE
    J Med Chem; 1989 Oct; 32(10):2318-25. PubMed ID: 2795605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diazepam inhibits cholesterol esterification by arterial ACAT and plasma LCAT, in vitro.
    Bell FP
    Atherosclerosis; 1984 Mar; 50(3):345-52. PubMed ID: 6712779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
    O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
    J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbits.
    Aragane K; Kojima K; Fujinami K; Kamei J; Kusunoki J
    Atherosclerosis; 2001 Sep; 158(1):139-45. PubMed ID: 11500184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carnitine ester hydrolysis in arteries from normal and cholesterol-fed rabbits and the effects of carnitine esters on arterial microsomal ACAT.
    Bell FP
    Comp Biochem Physiol B; 1984; 79(2):125-8. PubMed ID: 6509906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?
    Heinonen TM
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1519-27. PubMed ID: 12437499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterocyclic amides: inhibitors of acyl-CoA:cholesterol O-acyl transferase with hypocholesterolemic activity in several species and antiatherosclerotic activity in the rabbit.
    White AD; Purchase CF; Picard JA; Anderson MK; Mueller SB; Bocan TM; Bousley RF; Hamelehle KL; Krause BR; Lee P; Stanfield RL; Reindel JF
    J Med Chem; 1996 Sep; 39(20):3908-19. PubMed ID: 8831757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.
    Uchida T; Aoyama K; Watanabe T; Higuchi S
    Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall.
    Matsuo M; Ito F; Konto A; Aketa M; Tomoi M; Shimomura K
    Biochim Biophys Acta; 1995 Dec; 1259(3):254-60. PubMed ID: 8541332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.